Indeed, Jamroz–Wisniewska et al. [129] have observed that PON1 activity was significantly lower in patients with recurrent-remitting multiple sclerosis (RRMS) in relapse compared to other types of MS (RRMS patients in remission and progressive patients with RRMS), and that hypercholesterolemia was observed in patients with MS. This evidence concerns the gene PON1 and myeloid sarcoma.